Metastatic Urothelial Carcinoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastatic urothelial carcinoma. 24 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
24
Active US patents
57/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Metastatic Urothelial Carcinoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson 24 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastatic urothelial carcinoma. Each bar = one year. Y-axis scaled to peak year (9 patents).

3
31
3
33
6
35
9
36
3
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Balversa
ERDAFITINIB
 Johnson & Johnson 24 57 $300M 2031-04-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12037644 Balversa method of use 75 2035-10-18
12037644 Balversa method of use 75 2035-10-18
12037644 Balversa method of use 75 2035-10-18
10478494 Balversa method of use 75 2036-08-13
10478494 Balversa method of use 75 2036-08-13
10478494 Balversa method of use 75 2036-08-13
11684620 Balversa method of use 70 2036-02-09
11684620 Balversa method of use 70 2036-02-09
11684620 Balversa method of use 70 2036-02-09
9464071 Balversa method of use 68 2031-04-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8895601 Balversa composition of matter 4 2033-04-12
8895601 Balversa composition of matter 4 2033-04-12
8895601 Balversa composition of matter 4 2033-04-12
9902714 Balversa formulation 42 2035-03-26
9902714 Balversa formulation 42 2035-03-26
9902714 Balversa formulation 42 2035-03-26
11077106 Balversa method of use 62 2038-02-02
11077106 Balversa method of use 62 2038-02-02
11077106 Balversa method of use 62 2038-02-02
10898482 Balversa method of use 62 2036-02-09

Related